Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.64 |
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TPMT | P51580 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20198260 | 1.00 | ALDH1A1 (0.76) | ALDH1A1LMNASRD5A2CES2CES1 | |
| SCHEMBL18652852 | 0.88 | LMNA (0.59) | ALDH1A1LMNASRD5A2CES2CES1 | |
| SCHEMBL9389844 | 0.87 | TPMT (0.65) | ALDH1A1LMNASRD5A2SMN1; SMN2TPMT | |
| SCHEMBL1244094 | 0.87 | TPMT (0.65) | ALDH1A1LMNASRD5A2SMN1; SMN2TPMT | |
| SCHEMBL3841301 | 0.87 | TPMT (0.65) | ALDH1A1LMNASRD5A2SMN1; SMN2TPMT | |
| SCHEMBL822185 | 0.87 | ALDH1A1 (1.00) | ALDH1A1LMNASRD5A2CES2CES1 | |
| SCHEMBL52200 | 0.87 | ALDH1A1 (1.00) | ALDH1A1LMNASRD5A2CES2CES1 | |
| Hydrochloric Acid SCHEMBL27909743 | 0.85 | ALDH1A1 (0.94) | ALDH1A1LMNASRD5A2CES2CES1 | |
| SCHEMBL11528213 | 0.85 | ALDH1A1 (0.94) | ALDH1A1LMNASRD5A2CES2CES1 | |
| SCHEMBL21230318 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNASRD5A2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350149-B1 | [(2-ETHOXY-5-TRANS-1-PROPEN-1-YL)-PHENOXYL]-TERMINATED COMPOUNDS | EVONIK DEGUSSA GMBH (DE) | 2019-11-20 | — | — | EP | disclosed |
| EP-2433989-B1 | LIGHT-ABSORBING MATERIAL AND PHOTOELECTRIC CONVERSION ELEMENT | PANASONIC CORP (JP) | 2018-03-14 | — | — | EP | disclosed |
| EP-3050885-B1 | BENZODIAZEPINE BROMODOMAIN INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2017108946-A1 | THERMOSETTING RESIN COMPOSITIONS | HEXCEL COMPOSITES LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
| US-20170145021-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC | 2017-05-25 | — | — | US | disclosed |
| US-20170145021-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC | 2017-05-25 | — | — | US | disclosed |
| WO-2017045931-A1 | [(2-ETHOXY-5-TRANS-1-PROPEN-1-YL)-PHENOXYL]-TERMINATED COMPOUNDS | EVONIK TECHNOCHEMIE GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| EP-3144289-A1 | [(2-ETHOXY-5-TRANS-1-PROPEN-1-YL)-PHENOXYL]-TERMINATED COMPOUNDS | Evonik Technochemie GmbH (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-9598420-B2 | Benzodiazepine bromodomain inhibitor | GLAXOSMITHKLINE LLC (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598420-B2 | Benzodiazepine bromodomain inhibitor | GLAXOSMITHKLINE LLC (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150299210-A1 | Benzodiazepine Bromodomain Inhibitor | GLAXOSMITHKLINE LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299210-A1 | Benzodiazepine Bromodomain Inhibitor | GLAXOSMITHKLINE LLC | 2015-10-22 | — | — | US | disclosed |
| US-9102677-B2 | Benzodiazepine bromodomain inhibitor | GLAXOSMITHKLINE LLC (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102677-B2 | Benzodiazepine bromodomain inhibitor | GLAXOSMITHKLINE LLC (US) | 2015-08-11 | — | — | US | disclosed |
| US-20120252781-A1 | Benzodiazepine Bromodomain Inhibitor | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252781-A1 | Benzodiazepine Bromodomain Inhibitor | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| WO-2012001131-A1 | METHOD OF MAKING POLY(ARYL ETHER KETONES) FROM 4,4' DIFLUOROBENZOPHENONE COMPRISING OXIDIZING SPECIES AND/OR NITRO COMPOUNDS | SOLVAY SPECIALTY POLYMERS USA, L.L.C. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011054845-A1 | BENZODIAZEPINE BROMODOMAIN INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-7927756-B2 | Redox fuel cell using methanol | FUJITSU LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299210-A1 | Benzodiazepine Bromodomain Inhibitor | GABRB1, GABRB3, GABRB2 | ALDH1A1 1074/4885LMNA 2329/4885SRD5A2 1449/4885 |
| US-20170145021-A1 | NOVEL COMPOUNDS | GABRE, GABRA1, GABRA6 | ALDH1A1 996/4885LMNA 2687/4885SRD5A2 621/4885 |
| US-20120252781-A1 | Benzodiazepine Bromodomain Inhibitor | GABRB1, GABRB3, GABRB2 | ALDH1A1 1074/4885LMNA 2329/4885SRD5A2 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.